Assembly Biosciences nominates first herpesvirus candidate ABI-5366, a long-acting HSV-2 helicase inhibitor

ASSEMBLY BIOSCIENCES, INC.

ABI-5366 is a long-acting HSV-2 helicase inhibitor targeting high-recurrence genital herpes; IND-enabling studies initiated.
Preclinical data show nanomolar potency in vitro and exceptionally low clearance, supporting at least monthly dosing.
Company plans to file IND/CTA in first half of 2024; more data expected at scientific conferences in 2023.
First development candidate from Assembly Bio's expanded focus beyond hepatitis B.
Current therapies for high-recurrence genital herpes are only partially effective; helicase inhibitors previously showed greater reductions in shedding and lesions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.